Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SGBI Stock Summary
In the News
SGBI Financial details
Company Rating
Neutral
Market Cap
733.61K
Income
-165.12K
Revenue
80.86K
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
10 May 2021
P/E
-3.11
Forward P/E
-
PEG
0.93
P/S
8.65
P/B
-1.72
P/C
-
P/FCF
-29.64
Quick Ratio
0.03
Current Ratio
0.04
Debt / Equity
-2.35
LT Debt / Equity
-0.07
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-108.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-2.15%
Revenue Q/Q
75.94%
EPS Q/Q
-50%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-220%
ROE
67%
ROC
0.07%
Gross Margin
100%
Oper. Margin
-95%
Profit Margin
-278%
Payout
-
Shs Outstand
209.9M
Shs Float
182.54M
-
-
-
-
Target Price
-
52W Range
0.002-0.02
52W High
-
52W Low
-
RSI
43.39
Rel Volume
0.03
Avg Volume
3.01K
Volume
100
Perf Week
0%
Perf Month
3.57%
Perf Quarter
-
Perf Half Y
5.45%
-
-
-
-
Beta
0.198
-
-
Volatility
0%, 0%
Prev Close
-16.91%
Price
0.0029
Change
-16.91%
SGBI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-06-30
Metric | History | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 2.82M | 2.78M | 2.92M | 4.51M | 2.09M | |
Enterprise value | 3.05M | 3.23M | 3.59M | 5.3M | 2.88M | |
P/E ratio | -13.99 | -8.77 | -13.33 | -19.12 | 124.21 | |
Price to sales ratio | 36.59 | 31.58 | 100.82 | 68.81 | 30.15 | |
POCF ratio | -11.12 | -8.77 | -17.31 | -30.94 | -14.85 | |
PFCF ratio | -11.12 | -8.77 | -17 | -30.94 | -14.85 | |
P/B Ratio | 10.41 | 56.49 | -35.17 | -20.19 | -8.72 | |
PTB ratio | 10.41 | 56.49 | -35.17 | -20.19 | -8.72 | |
EV to sales | 39.49 | 36.71 | 124.28 | 80.85 | 41.63 | |
Enterprise value over EBITDA | -15.74 | -9.57 | -19.94 | -35.27 | -23.57 | |
EV to operating cash flow | -12.01 | -10.19 | -21.34 | -36.36 | -20.51 | |
EV to free cash flow | -12.01 | -10.19 | -20.96 | -36.36 | -20.51 | |
Earnings yield | -0.07 | -0.11 | -0.08 | -0.05 | 0.01 | |
Free cash flow yield | -0.09 | -0.11 | -0.06 | -0.03 | -0.07 | |
Debt to equity | 0.9 | 9.72 | -8.37 | -3.67 | -3.45 | |
Debt to assets | 2.39 | 6.06 | 5.53 | 6.11 | 6.31 | |
Net debt to EBITDA | -1.15 | -1.34 | -3.76 | -5.25 | -6.5 | |
Current ratio | 0.23 | 0.12 | 0.06 | 0.07 | 0.07 | |
Interest coverage | -25.04 | -28.89 | -12.87 | -8.4 | -7.2 | |
Income quality | 1.26 | 0.93 | 0.85 | 0.72 | 2.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.4 | 4.53 | 6.94 | 3.17 | 2.88 | |
Research and developement to revenue | 0.3 | 0.31 | 0.29 | 0.13 | 0.12 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.02 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.11 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0.29 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.01 | 0 | 0 | 0.01 | 0 | |
ROIC | -0.38 | -0.59 | -0.29 | -0.26 | 0.06 | |
Return on tangible assets | -1.98 | -4.01 | -1.75 | -1.76 | 0.13 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | -351.14K | -591.99K | -742.79K | -888.04K | -867.91K | |
Tangible asset value | -351.14K | -591.99K | -729.88K | -875.33K | -894.96K | |
Net current asset value | -351.14K | -591.99K | -806.51K | -942.78K | -958.04K | |
Invested capital | 0.9 | 9.72 | -8.37 | -3.67 | -3.45 | |
Average receivables | 34.22K | 50.18K | 31.05K | 22.47K | 25.15K | |
Average payables | 189.3K | 176.94K | 141.7K | 123.28K | 127.85K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 275.87 | 174.4 | 253.13 | 138.45 | 134.09 | |
Days payables outstanding | 1.12M | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.32 | 2.09 | 1.44 | 2.64 | 2.72 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.74 | -6.44 | 2.64 | 1.06 | -0.07 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q3
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 3.98M | 2.04M | 2.41M | 925.9K | 965.8K | |
Enterprise value | 4.79M | 2.84M | 3.17M | 1.75M | 1.79M | |
P/E ratio | -66.9 | 16.73 | 9.38 | -1.3 | -2.95 | |
Price to sales ratio | 221.52 | 194.39 | 58.85 | 87.13 | 51.66 | |
POCF ratio | -160.53 | -54.69 | -93.99 | 188.96 | 3.85K | |
PFCF ratio | -160.53 | -54.69 | -93.99 | 188.96 | 3.85K | |
P/B Ratio | -16.68 | -8.54 | -11.64 | -2.94 | -2.73 | |
PTB ratio | -16.68 | -8.54 | -11.64 | -2.94 | -2.73 | |
EV to sales | 266.65 | 270.03 | 77.3 | 164.4 | 95.89 | |
Enterprise value over EBITDA | -147.25 | -211.66 | -274.78 | -76.8 | -99.37 | |
EV to operating cash flow | -193.24 | -75.97 | -123.46 | 356.55 | 7.14K | |
EV to free cash flow | -193.24 | -75.97 | -123.46 | 356.55 | 7.14K | |
Earnings yield | 0 | 0.01 | 0.03 | -0.19 | -0.08 | |
Free cash flow yield | -0.01 | -0.02 | -0.01 | 0.01 | 0 | |
Debt to equity | -3.68 | -3.45 | -3.68 | -2.64 | -2.35 | |
Debt to assets | 4.71 | 6.31 | 5.99 | 8.38 | 9.36 | |
Net debt to EBITDA | -24.93 | -59.29 | -65.59 | -36.1 | -45.84 | |
Current ratio | 0.12 | 0.07 | 0.08 | 0.04 | 0.04 | |
Interest coverage | -6.24 | -8.87 | -3.2 | -5.4 | -4.4 | |
Income quality | 1.6 | 3.81 | -1.03 | -0.05 | -0.01 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.46 | 5.33 | 1.33 | 3.41 | 2.18 | |
Research and developement to revenue | 0.11 | 0.2 | 0.06 | 0.16 | 0.04 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0.01 | 0 | |
ROIC | 0 | 0.23 | -0.07 | -0.08 | -0.09 | |
Return on tangible assets | -0.08 | 0.23 | 0.5 | -1.8 | -0.92 | |
Graham Net | 0 | 0 | 0 | 0 | -0.01 | |
Working capital | -861.21K | -867.91K | -838.16K | -946.3K | -988.12K | |
Tangible asset value | -891.91K | -894.96K | -861.5K | -970.11K | -1.01M | |
Net current asset value | -963.69K | -958.04K | -915.84K | -1.02M | -1.06M | |
Invested capital | -3.68 | -3.45 | -3.68 | -2.64 | -2.35 | |
Average receivables | 30.43K | 27.47K | 42.54K | 45.23K | 29.42K | |
Average payables | 129.17K | 128.47K | 139.06K | 152.71K | 166.01K | |
Average inventory | 0 | 0 | 0 | -7.96K | -7.96K | |
Days sales outstanding | 148.01 | 217.79 | 130.88 | 260.83 | 135.02 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.61 | 0.41 | 0.69 | 0.35 | 0.67 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.06 | -0.13 | -0.31 | 0.57 | 0.23 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SGBI Frequently Asked Questions
What is Sangui Biotech International, Inc. stock symbol ?
Sangui Biotech International, Inc. is a DE stock and trading under the symbol SGBI
What is Sangui Biotech International, Inc. stock quote today ?
Sangui Biotech International, Inc. stock price is $0.0029 today.
Is Sangui Biotech International, Inc. stock public?
Yes, Sangui Biotech International, Inc. is a publicly traded company.